when will compounded tirzepatide be unavailable Circle Medscape | The U.S. Food

June 6, 2026

Semaglutide, as injectable Wegovy, is FDA-approved to treat fatty liver disease in certain adults with liver fibrosis and for cardiovascular risk reduction in adults with heart disease and obesity or overweight

Tirzepatide works by targeting hormones that regulate hunger and blood sugar, helping you feel fuller longer and reducing food cravings

Nausea, constipation , and fatigue are the most commonly reported issues

If more than 4 days have passed, skip the missed dose and continue with your next scheduled dose

Adjusted population analysis finds tirzepatide more effective than semaglutide for weight loss Truveta Research then used multiple rigorous methods (including propensity score matching) to achieve a well-balanced analytic cohort of 18,000 patients to appropriately evaluate the effectiveness of semaglutide compared with tirzepatide for weight loss